These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 26895604)

  • 1. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation.
    Dong J; Xiong W; Chen Y; Zhao Y; Lu Y; Zhao D; Li W; Liu Y; Chen X
    Int J Antimicrob Agents; 2016 Mar; 47(3):202-9. PubMed ID: 26895604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal dosing regimen of biapenem based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation in patients with febrile neutropenia and haematological malignancies.
    Rao Q; Yang Y; Wang S; Zhu H; Jin L; Zhang J; Liu M
    Int J Antimicrob Agents; 2023 Jul; 62(1):106841. PubMed ID: 37160241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation.
    Hang Y; Chen Y; Xue L; Sun S; Liu L; Gao J; Xie C; Zhang X; Zhu J; Jin J; Miao L
    Int J Antimicrob Agents; 2018 Mar; 51(3):484-487. PubMed ID: 28709989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Analysis on the effective dosage regimens for meropenem, biapenem and doripenem against P. aeruginosa infection based on pharmacokinetics and pharmacodynamics theory].
    Sumitani Y; Kobayashi Y
    Jpn J Antibiot; 2007 Dec; 60(6):394-403. PubMed ID: 18447209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients.
    Ikawa K; Morikawa N; Ohge H; Ikeda K; Sueda T; Taniwaki M; Kurisu K
    J Infect Chemother; 2010 Feb; 16(1):25-32. PubMed ID: 20082106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units.
    Roos JF; Bulitta J; Lipman J; Kirkpatrick CM
    J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment.
    Ikawa K; Nakashima A; Morikawa N; Ikeda K; Murakami Y; Ohge H; Derendorf H; Sueda T
    Antimicrob Agents Chemother; 2011 Dec; 55(12):5609-15. PubMed ID: 21947393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic evaluation of biapenem in peritoneal fluid using population pharmacokinetic modelling and Monte Carlo simulation.
    Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T
    Int J Antimicrob Agents; 2008 Oct; 32(4):339-43. PubMed ID: 18602798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
    Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Morikawa N; Takeda Y
    J Infect Chemother; 2015 Apr; 21(4):284-9. PubMed ID: 25638291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem.
    Kuti JL; Horowitz S; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2005 Jul; 25(7):935-41. PubMed ID: 16006272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of biapenem against lower respiratory tract infections in elderly Chinese patients and optimal dosing regimen based on pharmacokinetic/pharmacodynamic analysis.
    Dong J; Chen YC; Xiong W; Zhao YF; Sun YB; Lu Y; Liu YH; Li WY; Chen XJ
    J Chemother; 2016 Oct; 28(5):403-10. PubMed ID: 26430768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic comparisons of antimicrobials against nosocomial isolates of escherichia coli, klebsiella pneumoniae, acinetobacter baumannii and pseudomonas aeruginosa from the MYSTIC surveillance program: the OPTAMA Program, South America 2002.
    Kiffer CR; Mendes C; Kuti JL; Nicolau DP
    Diagn Microbiol Infect Dis; 2004 Jun; 49(2):109-16. PubMed ID: 15183860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii.
    Jaruratanasirikul S; Nitchot W; Wongpoowarak W; Samaeng M; Nawakitrangsan M
    Eur J Pharm Sci; 2019 Aug; 136():104940. PubMed ID: 31132402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experimental verification of the efficacy of optimized two-step infusion therapy with meropenem using an in vitro pharmacodynamic model and Monte Carlo simulation.
    Eguchi K; Kanazawa K; Shimizudani T; Kanemitsu K; Kaku M
    J Infect Chemother; 2010 Feb; 16(1):1-9. PubMed ID: 20072800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics and pharmacodynamics of biapenem in paediatric patients.
    Ikawa K; Morikawa N; Ikeda K; Miki M; Nishimura S; Kobayashi M
    J Clin Pharm Ther; 2008 Apr; 33(2):203-10. PubMed ID: 18315787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics of High-Dose Continuous-Infusion Meropenem and Considerations for Use in the Treatment of Infections Due to KPC-Producing Klebsiella pneumoniae.
    Cojutti P; Sartor A; Righi E; Scarparo C; Bassetti M; Pea F
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Determine Optimal Dosing of Ceftazidime-Avibactam for the Treatment of Acute Pulmonary Exacerbations in Patients with Cystic Fibrosis.
    Bensman TJ; Wang J; Jayne J; Fukushima L; Rao AP; D'Argenio DZ; Beringer PM
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic-pharmacodynamic target attainment analysis of biapenem in adult patients: a dosing strategy.
    Ikawa K; Morikawa N; Ikeda K; Ohge H; Sueda T; Suyama H; Doi M; Kuwabara M
    Chemotherapy; 2008; 54(5):386-94. PubMed ID: 18769027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa.
    Kuti JL; Florea NR; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2004 Jan; 24(1):8-15. PubMed ID: 14740783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.
    Ramon-Lopez A; Allen JM; Thomson AH; Dheansa BS; James SE; Hanlon GW; Stewart B; Davies JG
    J Antimicrob Chemother; 2015 Mar; 70(3):882-90. PubMed ID: 25362574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.